Predictors of response to erenumab after 12 months of treatment-Reference-Cited by-同舟云学术

Predictors of response to erenumab after 12 months of treatment

Published:2021-07-16 Issue:8 Volume:11 Page:
ISSN:2162-3279
Container-title:Brain and Behavior
language:en
Short-container-title:Brain Behav

Author:

Baraldi Carlo¹^ORCID,Castro Flavia Lo²,Cainazzo Maria Michela³,Pani Luca³⁴⁵⁶,Guerzoni Simona³

Affiliation:

1. PhD School in Neuroscience Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia Modena Italy

2. Post‐graduate School of Pharmacology and Clinical Toxicology Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia Modena Italy

3. Medical Toxicology‐headache and Drug Abuse Research Center Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia Modena Italy

4. Pharmacology Unit Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia Modena Italy

5. Department of Psychiatry and Behavioral Sciences University of Miami Miami Florida USA

6. VeraSci Durham North Carolina USA

Publisher

Wiley

Subject

Behavioral Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/brb3.2260

Reference30 articles.

1. Short and Mid‐Term Predictors of Response to OnabotulinumtoxinA: Real‐Life Experience Observational Study

2. Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study;Barbanti P.;Headache,2020

3. Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns

4. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study

5. Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis;European Journal of Pharmacology;2024-08

2. Application of Artificial Intelligence in the Headache Field;Current Pain and Headache Reports;2024-07-08

3. Anti-CGRP monoclonal antibodies improve cognitive function in patients affected by chronic migraine complicated with medication overuse-headache;Confinia Cephalalgica;2024-05-07

4. Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients;Biomedicines;2024-03-18

5. Migraine treatment – updated recommendations 2024 –development of the Expert Group of the Headache Section ofthe Polish Neurological Society and the Polish Society for theStudy of Pain;BÓL;2024-03-18